These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2595770)

  • 1. Calcium channel blockers and cyclosporine metabolism.
    McNally P; Mistry N; Idle J; Walls J; Feehally J
    Transplantation; 1989 Dec; 48(6):1071. PubMed ID: 2595770
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of cyclosporine metabolism by other drugs in vitro.
    Henricsson S; Lindholm A
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):569-71. PubMed ID: 3284104
    [No Abstract]   [Full Text] [Related]  

  • 3. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients.
    Tortorice KL; Heim-Duthoy KL; Awni WM; Rao KV; Kasiske BL
    Ther Drug Monit; 1990 Jul; 12(4):321-8. PubMed ID: 2396304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes.
    Tjia JF; Back DJ; Breckenridge AM
    Br J Clin Pharmacol; 1989 Sep; 28(3):362-5. PubMed ID: 2789931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of calcium channel blockers on the cyclosporine dose requirement in renal transplant recipients.
    Howard RL; Shapiro JI; Babcock S; Chan L
    Ren Fail; 1990; 12(2):89-92. PubMed ID: 2236731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of the counteraction by calcium channel blockers of cyclosporine nephrotoxicity.
    Hammoud SH; Alkhansa S; Mahjoub N; Omar AG; El-Mas MM; Eid AA
    Am J Physiol Renal Physiol; 2018 Sep; 315(3):F572-F582. PubMed ID: 29767558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP4A/CYP2C modulation of the interaction of calcium channel blockers with cyclosporine on EDHF-mediated renal vasodilations in rats.
    Hammoud SH; Omar AG; Eid AA; El-Mas MM
    Toxicol Appl Pharmacol; 2017 Nov; 334():110-119. PubMed ID: 28899749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients.
    Cantarovich M; Hiesse C; Lockiec F; Charpentier B; Fries D
    Clin Nephrol; 1987 Oct; 28(4):190-3. PubMed ID: 3319309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term effects of calcium antagonists on hemodynamics and cyclosporine pharmacokinetics in heart-transplant and kidney-transplant patients.
    Roy LF; East DS; Browning FM; Shaw D; Ogilvie RI; Cardella C; Leenen FH
    Clin Pharmacol Ther; 1989 Dec; 46(6):657-67. PubMed ID: 2689045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients.
    Sketris IS; Methot ME; Nicol D; Belitsky P; Knox MG
    Ann Pharmacother; 1994 Nov; 28(11):1227-31. PubMed ID: 7849332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical differentiation of nifedipine and other calcium antagonists.
    Ebner F; Donath M; Rämsch KD
    Arq Bras Cardiol; 1984 Jul; 43(1):5-12. PubMed ID: 6395839
    [No Abstract]   [Full Text] [Related]  

  • 12. Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.
    Vilpo J; Koski T; Vilpo L
    Haematologica; 2000 Aug; 85(8):806-13. PubMed ID: 10942926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of calcium channel blockers in the treatment of hypertension.
    Halperin AK; Cubeddu LX
    Am Heart J; 1986 Feb; 111(2):363-82. PubMed ID: 3511651
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclosporine A--calcium channels interaction: a possible mechanism for nephrotoxicity.
    Nagineni CN; Misra BC; Lee DB; Yanagawa N
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1358-62. PubMed ID: 3824499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of nifedipine on renal function in normotensive cyclosporin-A-treated renal allograft recipients.
    McNally PG; Walls J; Feehally J
    Nephrol Dial Transplant; 1990; 5(11):962-8. PubMed ID: 2127834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An appraisal of drug interactions with Sandimmun.
    Cockburn IT; Krupp P
    Transplant Proc; 1989 Oct; 21(5):3845-50. PubMed ID: 2683269
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number.
    Brooks DP; Ohlstein EH; Contino LC; Storer B; Pullen M; Caltabiano M; Nambi P
    Eur J Pharmacol; 1991 Feb; 194(1):115-7. PubMed ID: 1647960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of cytochromes P-450 in cyclosporine metabolism.
    Watkins PB
    J Am Acad Dermatol; 1990 Dec; 23(6 Pt 2):1301-9; discussion 1309-11. PubMed ID: 2277139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effects of chloride channel blockers on thrombocytic cytoplasmic free calcium concentration and platelet aggregation].
    Yin SM; Chen XL; Nie DN; Xie SF; Ma LP; Wang XJ; Wu YD; Li YQ; Feng JH
    Zhonghua Xue Ye Xue Za Zhi; 2005 Mar; 26(3):170-4. PubMed ID: 15946532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.
    Sorkin EM; Clissold SP; Brogden RN
    Drugs; 1985 Sep; 30(3):182-274. PubMed ID: 2412780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.